Innovation Pharmaceuticals Inc (IPIX)

[frenchbroad]

It is correct. Compound 30 in this article is not Brilacidin.
This is Brilacidin:

Anti-Fungus
"Brilacidin combined with Caspofungin significantly clears A. fumigatus lung infection in an immunosuppressed murine model of invasive pulmonary aspergillosis. Brilacidin alone also decreases A. fumigatus fungal burden and ablates disease development in a murine model of fungal keratitis. Our results indicate that combinations of Brilacidin and antifungal drugs in clinical use are likely to improve the treatment outcome of aspergillosis and other fungal infections."
https://www.nature.com/articles/s41467-023-37573-y

Anti-Virus
"These data suggest that SARS-CoV-2 inhibition in these cell culture models is likely to be a result of the impact of Brilacidin on viral entry and its disruption of viral integrity. Brilacidin demonstrated synergistic antiviral activity when combined with Remdesivir. Collectively, our data demonstrate that Brilacidin exerts potent inhibition of SARS-CoV-2 against different strains of the virus in cell culture."
https://www.mdpi.com/1999-4915/13/2/271

Anti-Bacteria
"Brilacidin has shown great efficacy in phase II clinical trials against acute Staphylococcus aureus skin and skin structure infections, comparable to that of the lipopeptidic drug daptomycin, which is currently used clinically to treat drug-resistant staph infections (20). Brilacidin also has potent broad-spectrum activity in vitro against several other Gram-positive and Gram-negative pathogenic bacteria, including several multidrug-resistant strains (16, 21)."
https://journals.asm.org/doi/10.1128/aac.02955-14

Anti-Inflammation
"These additional data align with previously released Brilacidin-OM results showing a risk reduction in the incidence of SOM, including up to an 80.3% risk reduction in the incidence of SOM among patients receiving more aggressive chemotherapy. Other previously released results indicate Brilacidin-OM also delayed onset of SOM. The Company is developing Brilacidin-OM under FDA Fast Track designation as a convenient, and clearly differentiated, therapy aimed to decrease incidence of SOM."
http://www.cafepharma.com/cpwire/article/More-Promising-Data-from-Innovation-Pharmaceuticals-Phase-2-Brilacidin-Oral-Mucositis-Study/62772-

"A majority of patients treated with Brilacidin administered via retention enema achieved Clinical Remission (Modified Mayo scoring) in a Phase 2, open-label, Proof-of-Concept (PoC) clinical trial evaluating Brilacidin for UP/UPS. In addition, mucosal healing was evidenced by endoscopic review, an increasingly important measure toward establishing a drug’s efficacy."
https://www.bddpharma.com/innovation-pharmaceticals-phase-1-trial-of-brilacidin-for-ulcerative-colitis-meets-primary-endpoints-positive-topline-results-of-oral-brilacidin/

General
"“Brilacidin is now among our best options to fight antimicrobial resistant strains of bacterial infections, one of the scariest global threats,” explained Vincenzo Carnevale, professor of research at CST’s Institute for Computational Molecular Science (ICMS). He noted that the last truly novel class of antimicrobial molecules—not an optimization of preexisting molecules—was approved by the U.S. Food and Drug Administration in 1987."
https://news.temple.edu/news/2021-12-14/michael-l-klein-wins-prestigious-john-scott-award

Of course there is much much more. This only is a wee sample of independent study with Brilacidin. Also 3 successful and safe human clinical tests with 3 different administration method. There is not an other drug compound like it.
I think the time for Brilacidin partnership and advance and financial success is close now.